Product Description
PGN650 is a F(ab')2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29037107/)
Mechanisms of Action: Phosphatidylserine Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avid Bioservices
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01632696 |
PPHM 1201 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2016-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|